ARMP - AMEX

Armata Pharmaceuticals, Inc.

ARMP·AMEX

$7.93

+0.13%

HealthcareBiotechnology

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$291.12M

EPS-4.8000

P/E Ratio-1.65

Earnings Date08/11/2026

76.88M

Assets

-11%

3Y-29.0%

5Y+95.0%

10Y+323.0%

295.48M

Total Liabilities

120%

3Y+312.0%

5Y+1330.0%

10Y+3388.0%

-218.60M

Total Equity

355%

3Y-706.0%

5Y-1259.0%

10Y-2348.0%

Armata Pharmaceuticals, Inc. Funding & Solvency Profile

ARMP · AMEX

Current Assets

Cash & Cash Equivalents8.69M

Net Receivables472.00K

Inventory0.00

Other Current Assets1.51M

Total Current Assets11 M

Non-Current Assets

Property, Plant & Equipment46.10M

Goodwill & Intangible Assets13.75M

Long-Term Investments5.39M

Other Non-Current Assets973.00K

Total Non-Current Assets52 M

Total Assets

76.88M

Financial Health Analysis

Current Ratio

1.19x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Working Capital

2 M

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

14% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Armata Pharmaceuticals, Inc. Balance Sheet

ARMP • AMEX

Armata Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2008	Dec 2007	Dec 2006	Dec 2005	Dec 2004	Dec 2003
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	8.7M	9.3M	13.5M	14.9M	10.3M	9.6M	6M	8.2M	5.1M	5.7M	9.4M	6.6M	20.4M	862K	5.2M	16.4M	6.2M	14.1M	34.1M	21.1M
Cash & Short-Term Investments	8.7M	9.3M	13.5M	14.9M	10.3M	9.6M	6M	8.2M	5.1M	5.7M	9.4M	6.6M	20.4M	862K	5.2M	16.4M	6.2M	14.1M	34.1M	21.1M
Net Receivables	472K	744K	3.4M	1.9M	3M	561K	0.0	0.0	0.0	25K	125K	100K	8K	641K	317K	2.6M	1.5M	380K	404K	166K
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25K	125K	100K	8K	23K	317K	2.6M	1.5M	380K	404K	166K
Other Receivables	472K	744K	3.4M	1.9M	3M	561K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-619K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	1.7M	636K	0.0	251K	253K	602K	521K	339K	297K	148K	132K	243K	531K	683K	653K	409K
Other Current Assets	1.5M	1.3M	2.3M	10.3M	0.0	0.0	622K	0.0	253K	602K	521K	339K	171K	0.0	132K	0.0	0.0	0.0	653K	409K
Total Current Assets	10.7M	11.3M	19.2M	27M	15M	10.8M	6.7M	8.4M	5.4M	6.4M	10M	7M	20.5M	1.7M	5.7M	19.3M	8.2M	15.2M	35.2M	21.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	46.1M	54.9M	57.3M	46.7M	38.1M	12.8M	4.2M	503K	816K	1.1M	1.1M	1.2M	145K	136K	1.3M	1.1M	1.1M	1.7M	2.5M	3.4M
Goodwill	3.5M	3.5M	3.5M	3.5M	3.5M	3.5M	3.5M	0.0	0.0	0.0	7.6M	7.6M	4.3M	7.4M	0.0	7.9M	7.9M	31.6M	31.6M	0.0
Intangible Assets	10.3M	10.3M	10.3M	10.3M	10.3M	10.3M	10.3M	3M	4.9M	10.8M	12.8M	12.8M	12.9M	12.9M	0.0	0.0	0.0	0.0	0.0	31.6M
Goodwill & Intangible Assets	13.7M	13.7M	13.7M	13.7M	13.7M	13.7M	13.7M	3M	4.9M	10.8M	20.3M	20.4M	17.3M	20.3M	0.0	7.9M	7.9M	31.6M	31.6M	31.6M
Long-Term Investments	5.4M	5.5M	0.0	6M	0.0	1.2M	700K	800K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	12M	0.0	3M	0.0	-936K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	973K	975K	8.2M	2.4M	3M	-2.1M	135K	136K	0.0	0.0	0.0	0.0	0.0	0.0	200K	200K	206K	217K	668K	968K
Total Non-Current Assets	66.2M	75.1M	79.2M	80.8M	54.8M	28.7M	18.8M	3.5M	5.8M	11.8M	21.5M	21.6M	17.4M	20.4M	1.5M	9.2M	9.2M	33.6M	34.8M	36M
Total Assets	76.9M	86.4M	98.4M	107.9M	69.8M	39.5M	25.5M	11.9M	11.1M	18.2M	31.5M	28.6M	37.9M	22.1M	7.2M	28.5M	17.5M	48.8M	70M	57.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	921K	766K	1.6M	6M	1.1M	956K	547K	767K	578K	1.1M	1.4M	1.2M	2.1M	1.9M	1.7M	2.2M	1.9M	1.8M	1.3M	1.3M
Accounts Payable	921K	766K	1.6M	6M	1.1M	956K	547K	729K	578K	1.1M	1M	1.2M	2.1M	1.9M	0.0	2.2M	1.9M	1.8M	1.3M	1.3M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	38K	0.0	0.0	368K	0.0	0.0	0.0	1.7M	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	3.6M	4.1M	1.8M	2.2M	1.5M	1.3M	453K	1.1M	895K	308K	457K	0.0	465K	1M	2.1M	861K	2.4M	1M	1.6M
Short Term Debt	4.6M	39M	0.0	17M	0.0	722K	1.3M	0.0	0.0	803K	0.0	0.0	0.0	3.6M	0.0	336K	1.1M	155K	1.3M	1.3M
Capital Lease Obligations (Current)	0.0	4.4M	9.5M	0.0	1.5M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	933K	245K	244K	0.0	0.0	1.2M	79K	251K	278K	0.0	1.2M
Other Current Liabilities	3.5M	529K	1.3M	0.0	0.0	1.9M	1.7M	1.4M	340K	826K	420K	0.0	0.0	0.0	0.0	0.0	1M	0.0	407K	1.4M
Total Current Liabilities	8.9M	48.2M	16.5M	24.9M	4.8M	6.7M	4.9M	2.6M	2M	3.6M	2.4M	1.9M	2.1M	6.1M	4M	4.7M	5.2M	4.6M	4M	6.7M
NON-CURRENT LIABILITIES
Long Term Debt	256.9M	55.4M	82.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	570K	8.2M	10.2M	11.2M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2K	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	3.1M	3.1M	3.1M	15.1M	3.1M	3.1M	3.1M	819K	1.1M	2.4M	3M	3.1M	0.0	3.1M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	1.3M	22K	292K	2.4M	13.4M	20.2M	50M	0.0	6.9M	7.6M	6.3M	5.4M	6M	5.5M
Total Non-Current Liabilities	286.5M	86.2M	114M	46.9M	39.6M	14M	6M	841K	1.4M	4.9M	16.4M	23.3M	50M	3.1M	6.9M	7.6M	6.9M	13.6M	16.2M	16.7M
Capital Lease Obligations	26.5M	32.1M	38.1M	31.8M	38M	12.4M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	570K	8.2M	10.2M	11.2M
Total Liabilities	295.5M	134.5M	130.4M	71.8M	44.4M	20.7M	10.9M	3.4M	3.4M	8.5M	18.8M	25.2M	52.2M	9.1M	10.9M	12.2M	12.1M	18.2M	20.2M	23.4M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-401.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.1M	18.2M	1.5M	12.3M	89K	0.0	0.0	0.0	0.0	0.0	0.0	750K
Common Stock	364K	362K	361K	361K	271K	187K	99K	323K	95K	165K	59K	2M	1.8M	669K	202K	198K	109K	857K	856K	662K
Additional Paid-In Capital	282.6M	279.4M	276.4M	275.5M	228M	198.4M	172M	414.5M	401.8M	391.1M	375.2M	363.5M	360.7M	332.8M	316.9M	316.2M	289.3M	279.8M	279.7M	249.4M
Retained Earnings	-501.5M	-327.7M	-308.8M	-239.8M	-202.9M	-179.7M	-157.5M	-406.3M	-394.2M	-381.4M	-362.5M	-362M	-387.2M	-320.5M	-320.9M	-300.2M	-284M	-250M	-230.8M	-216.6M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-11.1M	-18.2M	-1.5M	-12.3M	-65K	0.0	0.0	0.0	-39K	-21K	0.0	-750K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.2M	1.5M	12.3M	10.5M	0.0	0.0	0.0	0.0	0.0	0.0	750K
Total Stockholders' Equity	-218.6M	-48M	-32.1M	36.1M	25.4M	18.9M	14.6M	8.5M	7.7M	9.7M	12.7M	3.4M	-14.2M	12.9M	-3.8M	16.2M	5.4M	30.6M	49.8M	33.5M
Total Equity	-218.6M	-48M	-32.1M	36.1M	25.4M	18.9M	14.6M	8.5M	7.7M	9.7M	12.7M	3.4M	-14.2M	12.9M	-3.8M	16.2M	5.4M	30.6M	49.8M	34.2M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	750K
SUMMARY
Total Liabilities & Equity	76.9M	86.4M	98.4M	107.9M	69.8M	39.5M	25.5M	11.9M	11.1M	18.2M	31.5M	28.6M	37.9M	22.1M	7.2M	28.5M	17.5M	48.8M	70M	57.7M
Total Investments	5.4M	5.5M	0.0	6M	0.0	1.2M	700K	800K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	288M	126.5M	120.4M	48.8M	38M	13.2M	2.9M	0.0	0.0	803K	0.0	0.0	0.0	3.6M	0.0	336K	1.7M	8.3M	11.5M	12.5M
Net Debt	279.3M	117.2M	106.8M	34M	27.7M	3.5M	-3.2M	-8.2M	-5.1M	-4.9M	-9.4M	-6.6M	-20.4M	2.8M	-5.2M	-16.1M	-4.5M	-5.8M	-22.6M	-8.5M
Shares Outstanding	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800	36,329,800

SEC Filings

ARMP - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 27, 2026	June 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 27, 2026	April 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 02, 2026	April 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 25, 2026	March 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 19, 2026	March 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 23, 2026	February 23, 2026	2026	View Filing

Showing 1 to 10 of 514 filings

Related Guides

Blog Categories

Continue your ARMP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.